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The cytokines that contribute to airway inflammation, including interleukin-1b (IL-1b)and tumour necrosis factor a
(TNFa), might have key roles in the development of chronic obstructive pulmonary disease (COPD). Interleukin-1
receptor antagonist (IL—1RN), the physiological antagonist of IL-1b, is also known to play a crucial role in several
chronic inflammatory diseases. In this study, we investigated the association of the polymorphisms of IL-1b, IL-
1RN and TNFa with susceptibility to COPD.
To elucidate the genotype of the IL-1b polymorphisms at position7511 base and at the amino acid residue 105,
the IL-1RN polymorphism in intron 2, and TNFa polymorphism at position 7308, polymerase chain reaction
(PCR) and restriction enzyme fragment length polymorphism (RFLP) were performed on blood samples from both
patients with COPD (n=53) and control subjects (n=65).
There were no dierences on the allele and genotype frequency of IL-1b, IL-1RN, and TNFa between the two
groups.
We could not find a significant link between the polymorphism of TNFa, which was previously reported to be
associated with chronic bronchitis, and COPD. Furthermore, no association between genetic polymorphisms of
IL1-b and IL-1RN and individual susceptibility to COPD was found.
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Chronic obstructive pulmonary disease (COPD) is char-
acterized by irreversible airflow limitation in the lungs (1).
The most important risk factor for development of COPD
is tobacco smoking. However, the fact that only 10–20% of
chronic heavy smokers develop symptomatic COPD (2,3)
suggests that dierences of susceptibility to tobacco smoke
injury must exist, and the genetic factors are supposed to be
related to this individual susceptibility. Furthermore, the
recent study suggested that familial factors other than
protease inhibitor type might influence the development of
airflow obstruction and chronic bronchitis (4).Received 1 September 1999 and accepted in revised form 8
February 2000.
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0954-6111/00/090847+05 $35?00/0Interleukin -1b (IL-1b) is a member of the interleukin-1
family that has a broad spectrum of both beneficial and
harmful biological actions. It is rapidly synthesized by
monocytic phagocytes, which are major cellular compo-
nents of bronchoalveolar lavage of current smokers, when
they have been stimulated by microbial products or
inflammation. IL-1b is supposed to be one of the important
cytokines in irreversible airway obstruction in long-stand-
ing asthma-(5). IL-1b is also known to increase the
synthesis of the collagenase (6) that was reported to cause
the development of emphysema of mouse lungs (7).
Polymorphisms of IL-1b have been reported; a single
base polymorphism at -511 (8) and a biallelic polymorph-
ism in exon-5 defined by a silent T?C transition (9).
Mononuclear cells carrying one or two copies of the wild-
type alleles in exon-5 were reported to produce increased
amounts of IL-1b protein when stimulated with lipopoly-
saccharide (9).
The interleukin-1 receptor antagonist (IL-1RN) is a
protein that binds to IL-1 receptor, which inhibits the
binding of IL-1a and IL-1b to the IL-1 receptor. As a
consequence, the biological activity of these cytokines is# 2000 HARCOURT PUBLISHERS LTD
848 T. ISHII ET AL.neutralized in physiological and/or pathological immune
and inflammatory responses.
The IL-1RN polymorphism is characterized by two to six
repeats (variable number of tandem repeats, VNTR) of the
86-bp-long segment in the second intron of the gene (10).
The four-repeat allele (IL-1RN*1) is the most frequent
allele. In contrast, the two-repeat allele (IL-1RN*2), the
second most frequent allele, was found to be associated
with more severe clinical outcome in several chronic
inflammatory diseases, including systemic lupus erythema-
tosus (11), ulcerative colitis (12), alopecia areata (13), and
diabetic nephropathy (14).
Tumour necrosis factor a (TNFa) is also the major
cytokine that contributes to the airway inflammation. A
single base polymorphism at 7308 of TNFa has been
described (15). Recently, it has been reported that carriage
of the less common A allele confers a higher risk to the
development of chronic bronchitis (16). Although chronic
bronchitis is a part of COPD, the association of poly-
morphism of TNFa with susceptibility to COPD, or
tobacco-induced airway inflammation, has not been yet
confirmed.
In the current study, we investigated whether the
polymorphisms of IL-1b, IL-1RN and TNFa gene have
an association with development of COPD among smokers
by polymerase chain reaction (PCR)-based genotyping
assay.
Materials and methods
STUDY SUBJECTS
The patient group consisted of 53 male adults with COPD,
diagnosed in the Tokyo University Hospital and the
Juntendo University Hospital according to the guidelinesTABLE 1. Primers, annealing temperature and cycle number fo
bands of RFLP
Target site of
polymorphism
Sequence of primer
IL-1b at position 7511 TGGCATTGATCTGGTTCATC
GTTTAGGAATCTTCCCACTT
IL-1b at the amino acid
residue 105
GTTGTCATCAGACTTTGACC
TTCAGTTCATATGGACCAGA
IL-1RN polymorphism
in intron 2
CCCCTCAGCAACACTCCTAT
TCTTCCTGGTCTGCAGGTAA
TNF-a polymorphism
at position 7308
TCCCCAAAAGAAATGGAGGCA
GGTTTTGAGGGCCAT
GAGACGTCTGCTGGCTGGGTof the European Respiratory Society (1). The diagnosis was
based on signs and symptoms, the pulmonary function test
(including %FEV1?0, RV/TLC, DLCO) in the stable
condition and chest X-ray (including CT). There were no
asthma patients in the COPD group. Three quarters of
COPD patients were treated with methylxanthine, 2/3 with
inhaled anti-cholinergic agents, 1/4 with inhaled b-
adrenergic agonist and inhaled corticosteroid, 15% with
oral b-adrenergic agonist and less than 10% with oral
prednisone. The serum level of a1-antitrypsin in the
COPD group was within normal range [mean value 254?0
(SE 7?4 )(range: 159–391) mgdl71]. Sixty-five blood samples
of control subjects were obtained from the Health Check
Division at the Tokyo Kenbikyoin Clinic. None of them
had family members aected by COPD. To exclude the
eects of gender dierence and to match the smoking
history, all of them were male and current smokers free
from pulmonary diseases, and showed normal values in the
pulmonary function tests.
STUDY DESIGN
Genomic DNA was extracted from whole blood by
QIAamp Blood Kit (QIAGEN Inc., CA, U.S.A). PCR
and restriction enzyme fragment length polymorphism
(RFLP) assays were performed to genotype the IL-1b
polymorphisms at position 7511 base and at the amino
acid residue 105, the IL-1RN polymorphism in intron 2,
and TNFa polymorphism at position 7308. The primers
used for each PCR, annealing temperature and cycle
number for PCR, the restriction enzymes for restriction
enzyme length polymorphism (RFLP) and the length of
expected bands are shown in Table 1. AvaI was purchased
from TAKARA Inc., Tokyo, Japan. All other restriction
enzymes were purchased from New England BioLabs Inc,
MA, U.S.A.r PCR, and the restriction enzymes and length of expected
Annealing
temperature (8C)
and cycle number
Restriction
enzyme
Length of
expected bands (bp)
498C, 35 cycle AvaI Wild: 190, 115
Mutant: 305
518C, 40 cycle TaqI Wild: 136, 114
Mutant: 252
518C, 35 cycle IL-1RN*1: 685
IL-1RN*2: 515
IL-1RN*3: 775
IL-1RN*4: 600
IL-1RN*5: 870
ATA
G
608C, 35 cycle NcoI Wild: 326. 36
Mutant: 362
TABLE 2. Basic characteristics of the COPD and control
groups
COPD (n=53) Control (n=65)
Gender Male Male
Age (yr) 68?7+9?4 58?3+4?9
Pack-years 50?4+4?2 43?3+1?9
%VC 90?3+2?8 102?0+1?5
FEV1?0 / FVC 44?7+1?6 % 78?9+0?6 %
%FEV1?0 46?7+2?3 % 96?4+1?5 %
All values are represented as mean (SE).
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PCRs were carried out with a Program-temp-control
system PC-800 (Astec, Tokyo, Japan). Genomic DNA
(100 ng) was added to a mixture containing 11 pmol of each
primer, 0?5 U of AmpliTaq Gold with 1?5 m1 of 106PCR
buer (containing 25mM MgCl2) and 1?5 ml of
106dNTPmix (Perkin-Elmer Applied Biosystems Division,
CA, U.S.A) in a final volume of 15ml. The ‘auto-hot start’
was used to prevent non-specific priming in the first cycle of
PCR. Following an initial denaturation step at 958C for
12 min, 35 cycles of PCR were carried out (denaturation at
958C for 30 sec, annealing for 30 sec, elongation at 728C
for 60 sec),which were followed by 1 cycle of elongation at
728C for 5 min. The PCR products were digested with the
restriction enzyme, except for the IL-1RN genotyping
assay. All digests were electrophoresed on a gel with
3?5% Ultrapure Agarose (GibcoBRL, MD, U.S.A) con-
taining ethidium bromide.
ANALYSIS
The dierences in allele distribution and allele frequency
among each group were examined by the w2-test, with
the Fisher exact test when appropriate. The age, smoking
index expressed as pack-year (number of pack of tobacco
smoked per day 6 number of years smoked), and the
values of pulmonary function test in both COPD and
control subjects were compared using the unpaired
Student’s t-test. These analyses were performed by Stat-
View J-4.5 application program (SAS Institute Inc., NC,
U.S.A.).
P-values less than 0?05 were considered to be statistically
significant. All values are expressed as mean+SEM.
Results
Age, smoking history and results of pulmonary function
test of the COPD patients and control group are shown inTABLE 3. Distribution of 5’-region and exon-5 polymorphism o
Number of in
Homozygous
wild type
C–T polymorphism at position 7511
Control Group 16 (24%)
COPD Group 14 (26%)
Silent C–T polymorphism
at the amino acid residue 105
Control Group 58 (92%)
COPD Group 49 (88%)Table 2. The dierence of the means of the pack-years of
tobacco between these groups were not significant. The
mean of %FEV1.0 of the COPD group was 50% of the
control group (mean value 46?72?3%, 96?41?5%
respectively).
The results of the IL-1b polymorphisms at position -511
base and at the amino acid residue 105, the IL-1RN
polymorphism in intron 2, and TNFa polymorphism at
position -308 are summarized in Tables 3, 4 and 5
respectively. In the control group, the major allele
frequency of IL-1b polymorphisms at position 7511 base
and TNFa polymorphism at position 7308 was 0?45 and
0?99, respectively. Our results agree with those obtained by
previous reports in a Japanese population (17,18). The
frequency of IL-1RN*1 was 0?93, and this was also similar
to a previous Japanese report (19). The major allele
frequency of IL-1b polymorphisms at the amino acid residue
105 was 0?96, and this allele frequency has not yet been
reported in a Japanese population, and was much higher
than 0?74, the frequency in a Caucasian population (9).
Genotype and allele frequencies as well as carriage rates
of the two polymorphisms of IL-1b were similar in the
COPD and control groups (Table 3). There was also no
significant dierence on allele frequency of IL-1RN*2 and
distribution of the genotype of IL-1RN between the two
groups (Table 4). Furthermore, allele frequency of thef IL-1b genotypes in the COPD and control groups
dividuals (% of group)
Heterozygote Homozygous
mutant
Allele frequency
of wild type
27 (42%) 22 (33%) 0?45
29 (54%) 10 (19%) 0?53
7 (8%) 0 (0%) 0?95
4 (11%) 0 (0%) 0?96
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control groups (Table 5).
Discussion
In this study, we investigated whether polymorphisms of
IL-1b, IL-1RN and TNFa gene have an association with
the development of COPD. In the view of statistics, given
the large number of possible candidate genes for COPD, a
significance level of 5% will cause many false-positive
results. However, we could not find any dierences of the
distribution of polymorphisms between the COPD and
control groups. These cytokines and the antagonist were
reported to be associated with many chronic inflammatory
diseases, and these cytokines are also supposed to be
involved in the inflammatory component of COPD (20).
Chronic tobacco smoking is the major risk factor of the
development of COPD. However, only a small proportion
of smokers actually exhibit airflow limitation. Other
factors, particularly the genetic factors, are supposed to
be related to this individual susceptibility to tobacco
induced lung injury. Recently, genetic polymorphisms of
cytochrome P450 (21), microsomal epoxide hydrolase
(mEPHX) (22), were suggested to have an association with
emphysema. In addition, TNFa, one of the important
cytokines that have key roles in inflammation, was also
reported to be associated with chronic bronchitis (16).
Several studies on the polymorphisms of IL-1b were
previously performed in relation to the inflammatory bowel
disease (23), insulin-dependent diabetes mellitus (24), and
periodontal disease (25). However, the results were
controversial. The two-repeat allele of IL-1RN (IL-
1RN*2) was also reported to be associated with moreTABLE 4. Distribution of IL-1RN genotypes in the COPD
and control groups
Number of individuals (% of group)
IL-1RN Genotype
1, 1 1, 2 2, 2 1, 3
Control group 57 (88%) 6 (9%) 1 (2%) 1 (2%)
COPD Group 49 (92%) 3 (6%) 1 (2%) 0 (0%)
TABLE 5. Distribution of TNF-a genotypes in the COPD and c
Number of in
Homozygous
wild type
H
G to A polymorphism at position 7308
Control Group 64 (98%)
COPD group 52 (99%)severe clinical outcome in several chronic inflammatory
diseases, including systemic lupus erythematosus (11),
ulcerative colitis (12), alopecia areata (13) and diabetic
nephropathy (14). The four-repeat (IL-1RN*1) and IL-
1RN*2 alleles are most common. The repeat region of IL-
1RN contains three potential protein-binding sites. There-
fore, the variable copy number of this repeat region may
have functional significance (10). Indeed, IL-1RN*2 was
reported to be associated with increased production of IL-
1RN protein, reduced production of IL-1a protein, and
enhanced productionof IL-1b by monocytes in vitro (26,
27). However, this study shows that there is no dierence
on the distribution of polymorphism of IL-1b and IL-1RN
between the COPD and control groups.
The TNFa gene is known to have the polymorphic site at
position 7308 (15). Although the actual eect of this
polymorphism in vivo has not been clearly demonstrated,
the less common A allele was shown to be a much more
powerful transcriptional activator than the common allele
(28). Positive association with the A allele was found in
some diseases, including cerebral malaria (29), dermatitis
herpetiformis (30) and chronic bronchitis (16). However, we
could not confirm an association between the polymorph-
ism at position 7308 of TNFa gene and COPD. Because
chronic bronchitis may not exactly be the same as
pulmonary emphysema in terms of pathophysiology and
tobacco-sensitivity, the polymorphism of TNFa may be
more related to infection-induced airway inflammation
rather than tobacco smoke-induced alveolar destruction.
In conclusion, we found no dierence in distributions of
the polymorphisms of IL-1b, IL-1RN and TNFa between
the COPD and control groups. Since the number of the
subjects examined in this study is limited, the further study
using a larger population is needed and other variations in
these genes should be investigated to clarify the association
of these genes with individual susceptibility to development
of COPD.
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